{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T13:58:05Z","timestamp":1769263085263,"version":"3.49.0"},"reference-count":96,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,4,13]],"date-time":"2017-04-13T00:00:00Z","timestamp":1492041600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Surgical Oncology"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec><jats:label\/><jats:p>Outcomes of pancreatic adenocarcinoma (PDA) remain dismal despite extensive clinical investigation. Combination chemotherapy provides modest improvements in survival above best supportive care, and immunotherapy has thus far not proven effective. Nevertheless, growing insight into antitumor immunity and the tumor microenvironment has inspired the discovery of novel agents targeting PDA. Oncolytic viruses represent an emerging class of immunotherapeutic agents that have undergone extensive preclinical investigation and warrant further investigation in well\u2010designed clinical trials.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jso.24626","type":"journal-article","created":{"date-parts":[[2017,4,13]],"date-time":"2017-04-13T18:34:00Z","timestamp":1492108440000},"page":"94-103","source":"Crossref","is-referenced-by-count":38,"title":["Oncolytic viral therapy for pancreatic cancer"],"prefix":"10.1002","volume":"116","author":[{"given":"Ahmad","family":"Rahal","sequence":"first","affiliation":[{"name":"Division of Hematology\u2010Oncology Department of Medicine Baylor College of Medicine Houston Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4997-1751","authenticated-orcid":false,"given":"Benjamin","family":"Musher","sequence":"additional","affiliation":[{"name":"Department of Medicine Dan L Duncan Comprehensive Cancer Center Baylor College of Medicine Houston Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,4,13]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21332"},{"key":"e_1_2_9_3_1","unstructured":"American Cancer Society.2016. Available at:https:\/\/www.cancer.org\/research\/cancer\u2010facts\u2010statistics.html."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.03.035"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.279201"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32409-6"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1985.01390320023003"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604838"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596"},{"key":"e_1_2_9_12_1","article-title":"Phase I\/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209\u2010040 [abstract]. In American Society of Clinical Oncologists (ASCO) 2015 annual meeting program: 2015 May 29\u2013June 2: Chicago","volume":"33","author":"El\u2010Khoueiry AB","year":"2015","journal-title":"J Clin Oncol"},{"key":"e_1_2_9_13_1","article-title":"CheckMate\u2010032: Phase I\/II, open\u2010label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A\/M) gastric cancer (GC). In American Society of Clinical Oncologists (ASCO) 2016 annual meeting program: 2016 June 3\u20137: Chicago","volume":"34","author":"Janjigian YY","year":"2016","journal-title":"J Clin Oncol"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.25"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3114"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5714"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005541"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.226092"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.01.007"},{"key":"e_1_2_9_20_1","unstructured":"Halozyme announces phase 2 study in advanced pancreas cancer meets key endpoints. Available at:http:\/\/www.halozyme.com\/investors\/news\u2010releases\/news\u2010release\u2010details\/2017\/Halozyme\u2010Announces\u2010Phase\u20102\u2010Study\u2010In\u2010Advanced\u2010Pancreas\u2010Cancer\u2010Meets\u2010KeyEndpoints\/default.aspx."},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0045"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.5.2756"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0369"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0175"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.5.3448"},{"key":"e_1_2_9_26_1","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/1078-0432.498.11.2","article-title":"Control of T\u2010cell\u2010mediated immune response by HLA class I in human pancreatic carcinoma","volume":"11","author":"Ryschich E","year":"2005","journal-title":"Clin Cancer Res"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054824"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm934"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013441"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(195305)6:3<591::AID-CNCR2820060317>3.0.CO;2-M"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(71)91186-X"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(71)92086-1"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.6272391"},{"key":"e_1_2_9_34_1","first-page":"473","article-title":"Studies in Hodgkin's syndrome; the association of viral hepatitis and Hodgkin's disease; a preliminary report","volume":"9","author":"Hoster HA","year":"1949","journal-title":"Cancer Res"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.4810.589"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(195209)5:5<1025::AID-CNCR2820050518>3.0.CO;2-Q"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300108"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1851332"},{"key":"e_1_2_9_39_1","first-page":"1666","article-title":"Phase III randomized clinical trial of intratumoral injection of E1B gene\u2010deleted adenovirus (H101) combined with cisplatin\u2010based chemotherapy in treating squamous cell cancer of head and neck or esophagus","volume":"23","author":"Xia ZJ","year":"2004","journal-title":"Ai Zheng"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.20.083001.084359"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/17.12.3351"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.2147\/OV.S39609"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4732"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302448"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302736"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.8.14.8934"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.232"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.8.1.7204"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-008-0543-0"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-2429"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2009.04.026"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301398"},{"key":"e_1_2_9_53_1","first-page":"348","article-title":"Systemic reovirus therapy of metastatic cancer in immune\u2010competent mice","volume":"63","author":"Hirasawa K","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2010.65"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132011"},{"key":"e_1_2_9_56_1","first-page":"2088","article-title":"Inhibition of the Raf\/MEK\/ERK pathway up\u2010regulates expression of the coxsackievirus and adenovirus receptor in cancer cells","volume":"63","author":"Anders M","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI37905"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2008"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1960"},{"key":"e_1_2_9_60_1","first-page":"3181","article-title":"A telomerase\u2010dependent conditionally replicating adenovirus for selective treatment of cancer","volume":"63","author":"Wirth T","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21846"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.262"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2009.05.006"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5286.373"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0697-639"},{"key":"e_1_2_9_66_1","first-page":"555","article-title":"A phase I\/II trial of intratumoral endoscopic ultrasound injection of ONYX\u2010015 with intravenous gemcitabine in unresectable pancreatic carcinoma","volume":"9","author":"Hecht JR","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_9_67_1","first-page":"3126","article-title":"Abrogation of the Rb\/p16 tumor\u2010suppressive pathway in virtually all pancreatic carcinomas","volume":"57","author":"Schutte M","year":"1997","journal-title":"Cancer Res"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2016.80"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1829-2"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1198443"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2213"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.79"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1091-255X(99)80021-3"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1091-255X(00)80106-7"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0045"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4352"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7701049"},{"key":"e_1_2_9_78_1","doi-asserted-by":"crossref","first-page":"9442","DOI":"10.1128\/jvi.71.12.9442-9449.1997","article-title":"The herpes simplex virus virulence factor ICP34.5 and the cellular protein MyD116 complex with proliferating cell nuclear antigen through the 63\u2010amino\u2010acid domain conserved in ICP34.5, MyD116, and GADD34","volume":"71","author":"Brown SM","year":"1997","journal-title":"J Virol"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1080\/13550280390218788"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2014.08.015"},{"key":"e_1_2_9_81_1","first-page":"1218","article-title":"Oncolytic viral therapy for human pancreatic cancer cells by reovirus","volume":"9","author":"Etoh T","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_9_82_1","first-page":"901","article-title":"Efficacy of oncolytic reovirus against liver metastasis from pancreatic cancer in immunocompetent models","volume":"27","author":"Himeno Y","year":"2005","journal-title":"Int J Oncol"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.3892\/or_00000364"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1518-0"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1088"},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24992"},{"key":"e_1_2_9_87_1","first-page":"31","article-title":"Oncolytic virus therapy for cancer","volume":"2","author":"Goldufsky J","year":"2013","journal-title":"Oncolytic Virother"},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-0533"},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2009.74"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.211"},{"key":"e_1_2_9_91_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.09.3672"},{"key":"e_1_2_9_92_1","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2011.30"},{"key":"e_1_2_9_93_1","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1999.0001"},{"key":"e_1_2_9_94_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0509341103"},{"key":"e_1_2_9_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.137"},{"key":"e_1_2_9_96_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.293"},{"key":"e_1_2_9_97_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-008-9924-z"}],"container-title":["Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjso.24626","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.24626","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T05:50:52Z","timestamp":1696398652000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jso.24626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,13]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1002\/jso.24626"],"URL":"https:\/\/doi.org\/10.1002\/jso.24626","archive":["Portico"],"relation":{},"ISSN":["0022-4790","1096-9098"],"issn-type":[{"value":"0022-4790","type":"print"},{"value":"1096-9098","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,13]]}}}